VERIPRED 20 Rx
Generic Name and Formulations:
Prednisolone (as sodium phosphate) 20mg/5mL; soln; dye- and alcohol-free; grape-flavor.
Indications for VERIPRED 20:
See literature. Individualize. Initially 5–60mg/day.
See literature. Individualize. Initially 0.14–2mg/kg/day in 3–4 divided doses.
Systemic fungal infections. Live vaccines.
May increase risk and mask signs of infection. Tuberculosis. Latent amebiasis. Strongyloides infestation. Ocular herpes simplex. Cerebral malaria. If exposed to chickenpox or measles, consider prophylaxis with immunoglobulin. Supplement with additional steroids in physiologic stress. Hypertension. Renal insufficiency. CHF. Hypothyroidism. Cirrhosis. Kaposi's sarcoma. Ulcerative colitis if perforation pending. Peptic ulcer. Diverticulitis. Intestinal anastomoses. Myasthenia gravis. Osteoporosis. Diabetes. Avoid abrupt cessation. May cause electrolyte imbalances, adrenocortical insufficiency, psychotic derangements. Use lowest effective dose. Monitor weight, growth, fluid and electrolyte balance, intraocular pressure. Elderly. Pregnancy (Cat.C). Nursing mothers.
Barbiturates, hydantoins, rifampin, ephedrine, other hepatic enzyme inducers may decrease effects. Potentiated by ketoconazole, estrogens (eg, oral contraceptives). Potentiates and potentiated by cyclosporine. Increased risk of GI effects with aspirin or other NSAIDs. Monitor oral anticoagulants. Excretion of salicylates may be increased. Caution with K+ depleting agents (eg, diuretics, amphotericin-B), digoxin, aspirin in hypoprothrombinemia. Withdraw anticholinesterases at least 24 hours before starting steroids. Adjust antidiabetic agents. May suppress reactions to skin tests.
HPA axis suppression, increased susceptibility to infection, glaucoma, cataracts, secondary infections, hypokalemia, hypocalcemia, hypernatremia, hypertension, CHF, psychic disorders, myopathy, osteoporosis, peptic ulcer, dermal atrophy, increased intracranial pressure, carbohydrate intolerance.
Sign Up for Free e-newsletters
- Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Handling Chemotherapy Premedications
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
- Adding Bevacizumab to First-line Chemotherapy Benefits Selects Cases of Ovarian Cancer
- Assessing Direct Costs of Treatment-Related Adverse Events in Advanced Melanoma
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|